Our Remarkable Journey

Exploring the Path to Advanced Wound Care Solutions

Our Journey

At Curada Bio, our story is one of scientific discovery and a strong commitment to improving healthcare. We started in 2022, driven by the belief that we could transform wound care through cutting-edge cell therapy.

Our journey began with the support of a significant DARPA grant, a testament to the innovative nature of our technology. DARPA invests in groundbreaking ideas, and this set us on a path to secure intellectual property licensed from Rice University and establish a robust supply chain and manufacturing process.

Embarking on an innovative journey, our product in development is designed to accelerate wound healing by modulating the immune system. Committed to scientific excellence, we are determined to redefine the approach to treating chronic wounds

Our Product

Our Commitment

Our Mission

At Curada Bio, our mission is to pioneer innovative solutions in wound care, leveraging cutting-edge technology to accelerate the healing process for chronic wounds. We are committed to pushing the boundaries of medical science to improve the lives of individuals affected by persistent wounds.

Our Vision

Our vision is to be at the forefront of regenerative medicine, revolutionizing wound care on a global scale. We aspire to set new standards for treatment efficacy, providing hope and healing to those who suffer from chronic wounds.

Our Values

  • Innovation
  • Collaboration
  • Integrity
  • Empathy

The Curada Bio Team

Susan Drapeau

Susan Drapeau, PhD

Co-Founder & CEO

Omid Veiseh

Omid Veiseh, PhD

Co-Founder, Scientific Advisor

Paul Wotton

Paul Wotton, PhD

Chairman of the Board

Tzahi Cohen-Karni

Tzahi Cohen-Karni, PhD

Co-Founder, Scientific Advisor

Our Team’s Impact in Figures

Team Synergy: Our collective expertise fuels Curada Bio’s innovation and progress in the wound care field.

0
FDA Clearances/
Approvals
0

Clinical Trials

0

Patent & Applications

0
Product Launches
(US & Global)
0M

Total Funds Raised

Tzahi Cohen-Karni, PhD

Co-Founder, Scientific Advisor

Tzahi Cohen-Karni is a Professor at the Departments of Biomedical Engineering and Materials Science engineering in Carnegie Mellon University, Pittsburgh PA USA. He received both his B.Sc. degree in Materials Engineering and the B.A. degree in Chemistry from the Technion Israel Institute of Technology, Haifa, Israel, in 2004. His M.Sc. degree in Chemistry from Weizmann Institute of Science, Rehovot, Israel, in 2006 and his Ph.D. in Applied Physics from the School of Engineering and Applied Sciences, Harvard University, Cambridge MA, USA, in 2011. He was a Juvenile Diabetes Research Foundation (JDRF) Postdoctoral Fellow at the Massachusetts Institute of Technology and Boston Children’s Hospital at the labs of Robert Langer and Daniel S. Kohane from 2011 to 2013. Dr. Cohen-Karni received the 2012 International Union of Pure and Applied Chemistry Young Chemist Award. In 2014, he was awarded the Charles E. Kaufman Foundation Young Investigator Research Award. In 2016, Dr. Cohen-Karni was awarded the NSF CAREER Award. In 2017, Dr. Cohen-Karni was awarded the Cellular and Molecular Bioengineering Rising Star Award, The Office of Naval Research Young Investigator Award and The George Tallman Ladd Research Award. In 2018, Dr. Cohen-Karni was awarded the Cellular and Molecular Bioengineering Young Innovator Award. In 2019, Dr. Cohen-Karni was awarded the Carnegie Institute of Technology (CIT) Dean’s Early Career Fellowship.Professor Cohen-Karni received the Gold Graduate Student Award from the Materials Research Society in 2009, and the 2012 International Union of Pure and Applied Chemistry Young Chemist Award. In 2014, he was awarded the Charles E. Kaufman Foundation Young Investigator Research Award. In 2016, Dr. Cohen-Karni was awarded the NSF CAREER Award.

Jordana Szpiro

Clinical Advisor

Dr. Jordana Szpiro, DPM, FACFAS was raised in Southern California. She obtained her Bachelor of Science in Biology from the University of California at Irvine. After graduating, she went on to receive her Doctorate of Podiatric Medicine from the California College of Podiatric medicine. Dr. Szpiro then completed her residency at Weill Medical College of Cornell University in New York City. During her residency, she advanced her education in the surgical management of common foot disorders including bunions, bone spurs, neuromas, and heel spurs.

As an established Boston podiatrist, Dr. Szpiro is board certified in Foot Surgery and has been practicing for over 24 years. She is a Diplomate of the American Board of Podiatric Surgery and a Fellow of the American College of Foot and Ankle Surgeons. Dr. Szpiro is a frequent lecturer and has spoken at various events, such as the APMA Annual Scientific Meeting where she discussed the use of lasers in treating toenail fungus. She will soon be discussing Sports Medicine at one of Boston’s prominent athletic clubs. Dr. Szpiro is affiliated with Beth Israel Deaconess Medical Center, Hallmark Health, Mt. Auburn Hospital, Cambridge Health Alliance, Melrose Wakefield and Lawrence Memorial Hospital in Medford.
Dr. Szpiro has accumulated extensive clinical and surgical experience throughout her career and is knowledgeable in working with patients of all ages. Living an active lifestyle herself through ballet, running, squash and skiing/snowboarding, she is particularly sensitive to the toll that athletic activities can take on one’s feet. Dr. Szpiro hopes to take her experiences and apply what she’s learned to providing patients with comprehensive and quality care. She also sees children and pediatric patients.

Paul Wotton

Chairman of the Board

Dr. Paul K. Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO, Board Member, named inventor and entrepreneur. He has extensive experience in strategic growth management, business transactions and product development. Dr. Wotton serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL), Cynata Therapeutics (ASX: CYP), Kytopen (Chairman), Combined Therapeutics and is a Co-Founder and Director of Avenge Bio., a clinical stage biotechnology company. Dr. Wotton was President and CEO of Ocata Therapeutics (NASDAQ:OCAT) until its acquisition by Astellas Pharma in 2016. Paul was named as a “Top 100 Innovation CEO” by World Biz Magazine and won the Ernst & Young Entrepreneur of the Year Regional (NJ) Life Sciences award in 2014.

Jeremy Goverman, MD

Clinical Advisor

Dr. Goverman is triple board certified in General Surgery, Critical Care, and Plastic Surgery. He is also a fellowship trained burn surgeon and a fellow of the American Burn Association (FABA). This training has allowed him to provide high quality burn and wound care from the moment of injury, throughout the acute hospitalization, and beyond discharge into the reconstructive period. For more than 15 years, he has been a part of the multidisciplinary team of burn care providers at the Massachusetts General Hospital (MGH) Sumner Redstone Burn Center, the Fraser Outpatient Burn Center, as well as the Shriners Burn Hospital in Boston. Dr. Goverman is the Director of the Acute and Reconstructive Burn Fellowship and is the Medical Director of the MGH Wound Center. In addition to a busy clinical practice, he has been involved in several burn and wound related projects including NIH and DOD funded basic science and clinical research trials. Dr. Goverman has more than 100 publications including research, book chapters, and other articles related to his work.

David Moller, MD

Clinical Advisor

David Moller is a physician-scientist with extensive biopharmaceutical R&D experience across a range of therapeutic areas and modalities. His C-suite leadership experience in biotech includes discovery and development oversight at - Variant Bio (genetics-driven drug discovery; current CSO), Poxel (clinical stage) and Sigilon Therapeutics (novel cell therapy platform).
David's experience also includes R&D leadership roles in large pharma. As a VP at Merck, David’s team discovered and delivered pipeline additions – including sitagliptin (JanuviaTM). As a global therapeutic area leader at Lilly, his team delivered several key products including: dulaglutide (TrulicityTM), tirzepatide (MounjaroTM, ZepboundTM), and LyumjevTM - plus Phase II-III molecules targeting musculoskeletal, urologic and cardiorenal disorders. At Lilly, David also served as VP, Business Development (a role focusing on access to early phase external innovation and venture investing). He has also held additional recent roles including as Director at Forkhead Biotherapeutics; SAB member at: Axcella Health, Avenge Bio, Avilar, Six Peaks; and as strategic advisor to TVM Capital.
David received a B.S. from Brown University and M.D. from U. of Cincinnati. He completed training programs at George Washington U. and Harvard and he’s also served on the Harvard faculty for several years. David has published more than 140 peer-reviewed papers; his honors include election to the American Society of Clinical Investigation, the Association of American Physicians, and appointment as an adjunct professor at the Karolinska Institute.

Discover Veiseh Lab

Omid Veiseh, PhD

Co-Founder, Scientific Advisor

Dr. Omid Veiseh, Ph.D., is an Associate Professor and CPRIT Scholar in Cancer Research in the Department of Bioengineering at Rice University. He leads an interdisciplinary translational research program to engineer and commercialize next-generation cell-based therapeutics for various human diseases. His team leverages the latest techniques in synthetic biology, immunoengineering, and materials science to develop innovative cell-based platforms for real-time and feedback-regulated production of biologics. Over the course of his career, he has authored or co-authored more than 75 peer-reviewed publications, including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, and Nature Biomedical Engineering, and is an inventor on more than 40 pending or awarded patents. He is also a serial entrepreneur who has co-founded Sigilon Therapeutics (Nasdaq: SGTX), Avenge Bio, Sentinel Bio, and Curada Bio. These companies collectively have attracted ~ $500M in private and public investment capital. In September of 2023, he was named the Director of Rice University's Biotech Launch Pad, a new initiative with a mission to accelerate the translation of Rice University discoveries and technologies into clinical practice to provide rapid patient access to leading-edge therapeutic products.

Susan Drapeau, PhD

Co-Founder & CEO

Susan Drapeau, Ph.D., has 25+ years of experience in cell therapy, biologics, biomaterials, and medical device development. Susan has been working with many clients in development, regulatory, business, and strategy at Bruder Consulting & Venture Group. She led development at Sigilon Therapeutics, combining biomaterials and cellular engineering for rare disease. At Vericel, Susan led business development, evaluating technologies for cartilage and wound repair. She spent 14 years at Medtronic managing biologics product development, launching products, gaining 510(k) clearances, submitting INDs, supporting manufacturing, due diligence, intellectual property. At Osiris Therapeutics she led bone product development using allogeneic cell therapies in combination with biomaterials.